[
    [
        {
            "time": "2018-03-15",
            "original_text": "Edwards Lifesciences Gets CE Mark Approval for Its Centera Valve",
            "features": {
                "keywords": [
                    "Edwards Lifesciences",
                    "CE Mark",
                    "Centera Valve",
                    "Approval"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Edwards Lifesciences Gets CE Mark Approval for Its Centera Valve",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-02-20",
            "original_text": "Johnson & Johnson’s Business Segments in 2017",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Business Segments",
                    "2017"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "consumer health",
                    "medical devices"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Johnson & Johnson’s Business Segments in 2017",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 2,
                "Headline_Structure": 5,
                "Source_Recenity": 2
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Varian’s HyperArc: Driven by Rising Metastatic Brain Cancer?",
            "features": {
                "keywords": [
                    "Varian",
                    "HyperArc",
                    "Metastatic Brain Cancer"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "oncology",
                    "radiation therapy"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Varian’s HyperArc: Driven by Rising Metastatic Brain Cancer?",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]